ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis.
Emre YekedüzElif Berna KoksoyHakan AkbulutYuksel UrunGungor UtkanPublished in: Future oncology (London, England) (2020)
Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on 31 March 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.
Keyphrases
- prognostic factors
- circulating tumor
- systematic review
- cell free
- circulating tumor cells
- case control
- end stage renal disease
- stem cells
- chronic kidney disease
- ejection fraction
- electronic health record
- early stage
- randomized controlled trial
- newly diagnosed
- machine learning
- patient reported outcomes
- replacement therapy
- drug induced